Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))

J. Vansteenkiste; T. Reungwetwattana; K. Nakagawa; B. C. Cho; M. A.Cobo Dols; E. K. Cho; A. Bertolini; S. Bohnet; C. Zhou; K. H. Lee; N. Nogami; I. Okamoto; N. Leighl; R. Hodge; A. McKeown; A. P. Brown; Y. Rukazenkov; S. Ramalingam

doi:10.1093/annonc/mdx782

Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))

J. Vansteenkiste, T. Reungwetwattana, K. Nakagawa, B. C. Cho, M. A.Cobo Dols, E. K. Cho, A. Bertolini, S. Bohnet, C. Zhou, K. H. Lee, N. Nogami, I. Okamoto, N. Leighl, R. Hodge, A. McKeown, A. P. Brown, Y. Rukazenkov, S. Ramalingam

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

3 Citations (Scopus)

Abstract

Ann Oncol 2017; 28: x7 (doi: 10.1093/annonc/mdx729) In the abstract LBA5, the names of authors A. Bertolini and Y. Rukazenkov were originally misspelt. They have now been corrected.

Original language	English
Pages (from-to)	x196
Journal	Annals of Oncology
Volume	28
DOIs	https://doi.org/10.1093/annonc/mdx782
Publication status	Published - 2017 Nov

Bibliographical note

Publisher Copyright:
© 2018 THE AUTHORS

All Science Journal Classification (ASJC) codes

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdx782

Fingerprint

Dive into the research topics of 'Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))'. Together they form a unique fingerprint.

Cite this

Vansteenkiste, J., Reungwetwattana, T., Nakagawa, K., Cho, B. C., Dols, M. A. C., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., Okamoto, I., Leighl, N., Hodge, R., McKeown, A., Brown, A. P., Rukazenkov, Y., & Ramalingam, S. (2017). Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729)). Annals of Oncology, 28, x196. https://doi.org/10.1093/annonc/mdx782

Vansteenkiste, J. ; Reungwetwattana, T. ; Nakagawa, K. et al. / Erratum : CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729)). In: Annals of Oncology. 2017 ; Vol. 28. pp. x196.

@article{549be29c60f14a95af8478e911964338,

title = "Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))",

abstract = "Ann Oncol 2017; 28: x7 (doi: 10.1093/annonc/mdx729) In the abstract LBA5, the names of authors A. Bertolini and Y. Rukazenkov were originally misspelt. They have now been corrected.",

author = "J. Vansteenkiste and T. Reungwetwattana and K. Nakagawa and Cho, {B. C.} and Dols, {M. A.Cobo} and Cho, {E. K.} and A. Bertolini and S. Bohnet and C. Zhou and Lee, {K. H.} and N. Nogami and I. Okamoto and N. Leighl and R. Hodge and A. McKeown and Brown, {A. P.} and Y. Rukazenkov and S. Ramalingam",

note = "Publisher Copyright: {\textcopyright} 2018 THE AUTHORS",

year = "2017",

month = nov,

doi = "10.1093/annonc/mdx782",

language = "English",

volume = "28",

pages = "x196",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Vansteenkiste, J, Reungwetwattana, T, Nakagawa, K, Cho, BC, Dols, MAC, Cho, EK, Bertolini, A, Bohnet, S, Zhou, C, Lee, KH, Nogami, N, Okamoto, I, Leighl, N, Hodge, R, McKeown, A, Brown, AP, Rukazenkov, Y & Ramalingam, S 2017, 'Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))', Annals of Oncology, vol. 28, pp. x196. https://doi.org/10.1093/annonc/mdx782

Erratum : CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729)). / Vansteenkiste, J.; Reungwetwattana, T.; Nakagawa, K. et al.

In: Annals of Oncology, Vol. 28, 11.2017, p. x196.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Erratum

T2 - CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))

AU - Vansteenkiste, J.

AU - Reungwetwattana, T.

AU - Nakagawa, K.

AU - Cho, B. C.

AU - Dols, M. A.Cobo

AU - Cho, E. K.

AU - Bertolini, A.

AU - Bohnet, S.

AU - Zhou, C.

AU - Lee, K. H.

AU - Nogami, N.

AU - Okamoto, I.

AU - Leighl, N.

AU - Hodge, R.

AU - McKeown, A.

AU - Brown, A. P.

AU - Rukazenkov, Y.

AU - Ramalingam, S.

PY - 2017/11

Y1 - 2017/11

N2 - Ann Oncol 2017; 28: x7 (doi: 10.1093/annonc/mdx729) In the abstract LBA5, the names of authors A. Bertolini and Y. Rukazenkov were originally misspelt. They have now been corrected.

AB - Ann Oncol 2017; 28: x7 (doi: 10.1093/annonc/mdx729) In the abstract LBA5, the names of authors A. Bertolini and Y. Rukazenkov were originally misspelt. They have now been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85045876106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045876106&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx782

DO - 10.1093/annonc/mdx782

M3 - Comment/debate

AN - SCOPUS:85045876106

SN - 0923-7534

VL - 28

SP - x196

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Dols MAC, Cho EK et al. Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729)). Annals of Oncology. 2017 Nov;28:x196. doi: 10.1093/annonc/mdx782